Latest Conference Articles

September 28th 2019, 2:46am

ESMO Congress

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.

September 28th 2019, 2:44am

ESMO Congress

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.

September 28th 2019, 1:23am

ESMO Congress

Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.

September 27th 2019, 11:58pm

ESMO Congress

Atezolizumab (Tecentriq) monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment of certain patients with wild-type non–small cell lung cancer.

September 27th 2019, 11:44pm

ESMO Congress

More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.

September 27th 2019, 11:01pm

ESMO Congress

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

September 20th 2019, 11:50pm

International Myeloma Society Annual Meeting

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

September 20th 2019, 11:41pm

International Myeloma Society Annual Meeting

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

September 16th 2019, 11:37pm

International Myeloma Society Annual Meeting

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

September 16th 2019, 9:13pm

International Myeloma Society Annual Meeting

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

September 16th 2019, 9:12pm

International Myeloma Society Annual Meeting

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

September 16th 2019, 8:59pm

International Myeloma Society Annual Meeting

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

September 16th 2019, 7:38pm

International Myeloma Society Annual Meeting

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.

September 16th 2019, 1:35am

International Myeloma Society Annual Meeting

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

September 15th 2019, 11:35pm

International Myeloma Society Annual Meeting

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

September 15th 2019, 11:11pm

International Myeloma Society Annual Meeting

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

September 15th 2019, 10:56pm

International Myeloma Society Annual Meeting

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.

September 15th 2019, 6:11pm

International Myeloma Society Annual Meeting

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

September 15th 2019, 3:25am

Society of Hematologic Oncology Annual Meeting (SOHO)

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

September 15th 2019, 3:13am

International Myeloma Society Annual Meeting

Adding the CD38-directed monoclonal antibody isatuximab in combination with pomalidomide and dexamethasone improved progression-free survival in both standard-risk patients with relapsed/refractory multiple myeloma and those with high-risk cytogenetics.